Code | CSB-RA289956A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:50-1:200 |
FC | 1:50-1:200 |
In order to develop a recombinant monoclonal antibody against ACTA1, CUSABIO initiated the process by immunizing a rabbit with a synthesized peptide derived from human ACTA1. Subsequently, B cells were isolated from the immunized rabbit, and RNA was extracted from these B cells. The extracted RNA was reverse-transcribed into cDNA, serving as a template for extending ACTA1 antibody genes using degenerate primers. These extended ACTA1 antibody genes were integrated into a plasmid vector and introduced into host cells for expression. The ACTA1 recombinant monoclonal antibody was then purified from the cell culture supernatant via affinity chromatography and assessed for its suitability in ELISA, IHC, and FC applications. It shows specific recognition of the human ACTA1 protein.
ACTA1 is a major component of the thin filaments in skeletal muscle fibers, where it interacts with myosin to generate the contractile force required for muscle contraction. Mutations in the ACTA1 gene can lead to various muscle disorders such as congenital myopathies.
There are currently no reviews for this product.